Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis organisms in cystic fibrosis

American Journal of Respiratory Medicine

Volumn 2, Issue 4, 2003, Pages 321-332

  Conway, Steven Philip ^a   Brownlee, Keith G ^a   Denton, Miles ^b   Peckham, Daniel G ^a  

^a SEACROFT HOSPITAL   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; MACROLIDE; MEROPENEM; METICILLIN; MINOCYCLINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ACHROMOBACTER; ACHROMOBACTER XYLOSOXIDANS; AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BRONCHUS; BURKHOLDERIA CEPACIA; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONCENTRATION (PARAMETERS); CYSTIC FIBROSIS; DETERIORATION; DISEASE EXACERBATION; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERANCE; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HEALTH CARE POLICY; HOSPITAL HYGIENE; HUMAN; IN VITRO STUDY; INDIVIDUALIZATION; LONGEVITY; LUNG FUNCTION; MAINTENANCE THERAPY; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; REVIEW; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0042887591     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256660     Document Type: Review

References (144)

1. Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, Geddes D, editors. Cystic fibrosis. London: Chapman and Hall, 1995: 1-13
2. Anonymous. Cystic Fibrosis Foundation Patient Registry 1999 annual data report. Bethesda (MD): Cystic Fibrosis Foundation, 2000
3. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-82
4. Armstrong DS, Grimwood K, Carling JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1197-204
5. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141: 914-21
6. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974 to 1995). Pediatr Pulmonol 1999; 28 (3): 159-66
7. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-74
8. Smith A, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone vs beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134: 413-21
9. Henwood CJ, Livermore DM, James D, et al. Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society of Antimicrobial Chemotherapy disk susceptibility test. J Antimicrob Chemother 2001; 47: 789-99
10. Blondeau JM, Suter ME, Borsos S, et al. The Canadian Pseudomonas Study Group. Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centres: focus on Ciprofloxacin. Int J Antimicrob Agents 1998; 10: 297-302
11. Consensus Conference. Microbiology and infectious disease in cystic fibrosis. Vol. V, section 1. Bethesda (MD): Cystic Fibrosis Foundation, 1994 May
12. Harris A, Torres-Viera C, Venkataraman L, et al. Epidemiology and clinical outcomes of patients with multi-resistant Pseudomonas aeruginosa. Clin Infect Dis 1999; 28: 1128-33
13. Doring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-67
14. Davey R, Peckham D, Etherington C, et al. Antibiotic resistance and clinical outcome following intravenous antibiotic therapy for respiratory exacerbation in cystic fibrosis. XIIIth International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. 185, A409
15. Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985; 132: 761-5
16. Dalhoff A, Doring G. Interference of ciprofloxacin with the expression of pathogenicity factors of Pseudomonas aeruginosa. In: Adam D, Hahn H, Opferkuch W, editors. The influence of antibiotics on the host-parasite relationship II. Berlin: Springer, 1985: 246-55
17. Grimwood K, To M, Rabin HR, et al. Inhibition of Pseudomonas aeruginosa exoenzyme expression by sub-inhibitory antibiotic concentrations. Antimicrob Agents Chemother 1989; 33: 41-7
18. Ogaard AR, Bjoro K, Bukholm G, et al. Pseudomonas aeruginosa virulence factors: modifications by sub-inhibitory concentrations of carbenicillin or gentamicin. Acta Pathol Microbiol Immunol Scand [B] 1986; 94: 63-8
19. Cheng K, Smyth RL, Govan JRW, et al. Spread of beta lactam resistance Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348: 639-42
20. Wu YL, Scott EM, Po ALW, et al. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 44: 389-92
21. Saiman L, Mehar F, Niau WW, et al. Antibiotics susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23: 532-7
22. Weiss K, Lapionte JR. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 2411-24
23. Lang BJ, Aaron SD, Ferris W, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000; 162: 2241-5
24. Shawar RM, MacLeod DL, Garber RL, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 2877-80
25. Whitehead A, Conway SP, Etherington C, et al. Once daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002; 19: 303-9
26. Vinks AA, Touw DJ, Heijerman HG, et al. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit 1994; 16: 341-8
27. Goldman M, Alcorn M. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by colistin. 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid. 1993: 114, A45
28. Conway SP, Pond MN, Watson A, et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987-93
29. Ledson MJ, Gallagher MJ, Cowperthwaite C, et al. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998; 12: 592-4
30. Kobyayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995; 99: 26S-30S
31. Kita E, Sawaki M, Oku D, et al. Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother 1991; 27: 273-84
32. Equi A, Bush A, Aton EW, et al. Long-term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled, crossover trial. Lancet 2002; 360: 978-84
33. Tummler B, Koopmann U, Grothues D, et al. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol 1991; 29: 1265-7
34. Mahenthiralingam E, Campbell ME, Foster J, et al. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996; 34: 1129-35
35. da Silva Filho LV, Levi JE, Bento CN, et al. Molecular epidemiology of Pseudomonas aeruginosa infections in a cystic fibrosis outpatient clinic. J Med Microbiol 2001; 50: 261-7
36. Tubbs D, Lenney W, Alcock P, et al. Pseudomonas aeruginosa in cystic fibrosis: cross-infection and need for segregation. Respir Med 2001; 95: 147-52
37. Pedersen SS, Koch C, Hoiby N, et al. An epidemic spread of multi-resistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986; 17: 505-16
38. Jones AM, Govan JRW, Doherty CJ, et al. Spread of a multiresistant strains of Pseudomomas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001; 358: 557-8
39. McCallum SJ, Corkill J, Gallagher M, et al. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet 2001; 358: 558-60
40. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002; 34: 257-61
41. Govan JR, Brown PH, Maddison J, et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342: 15-9
42. Smith DL, Gumery LB, Smith EG, et al. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol 1993; 31: 3017-22
43. Mahenthiralingam E, Baldwin A, Vandamme P. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol 2002; 51: 533-8
44. Coeyne T, Vandamme P, Govan JR, et al. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001; 39: 3427-36
45. Li Puma JJ. Current epidemiology of the Burkholderia cepacia complex [abstract]. Paediatr Pulmonol 2001; Suppl. 22: 155-6
46. Clode FE, Kaufmann ME, Malnick H, et al. Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol 2000; 38: 1763-6
47. Lipuma JJ, Spilker T, Gill LH, et al. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001; 164: 92-6
48. Chen JS, Witzmann KA, Spilker T, et al. Endemicity and inner-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001; 139: 643-9
49. Muhdi K, Edenborough FP, Gumery L, et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax 1996; 51: 374-7
50. Frangolias DD, Mahenthiralingam E, Rae S, et al. Burkholderia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med 1999; 160: 1572-7
51. Moore JE, Elborn JS. Burkholderia cepacia and cystic fibrosis: 50 years on. Commun Dis Public Health 2001; 4: 114-6
52. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163: 43-8
53. Li Puma JJ. Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis? Transpl Infect Dis 2001; 3: 149-60
54. De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001; 358: 1780-1
55. Aris RM, Routh JC, Lipuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Am J Respir Crit Care Med 2001; 164: 2102-6
56. Sajjan U, Corey M, Humar A, et al. Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients. J Med Microbiol 2001; 50: 535-46
57. Saini LS, Galsworthy SB, John MA, et al. Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation. Microbiology 1999; 145: 3465-75
58. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33: 1469-75
59. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-12
60. Bonacorsi S, Fitoussi F, Lhopital S, et al. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999; 43: 213-7
61. Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciproffoxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993; 37: 123-5
62. Kumar A, Hay MB, Maier GA, et al. Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia. J Antimicrob Chemother 1992; 30: 597-602
63. Kurlandsky LE, Fader RC. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis. Pediatr Pulmonol 2000; 29: 210-2
64. Alkawash M, Head M, Alshami I, et al. The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains. J Antimicrob Chemother 1999; 44: 385-7
65. Peckham DS, Crouch S, Humphreys H, et al. Effect of inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia. Thorax 1994; 49: 803-7
66. Peckham D, Leonard C, Range S, et al. Nutritional support and pulmonary function in patients with cystic fibrosis with and without Burkholderia cepacia colonization: role of specialist dietetic support. J Hum Nutr Diet 1996; 9: 173-9
67. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57-80
68. Denton M. Stenotrophomonas maltophilia: an emerging problem in cystic fibrosis patients. Rev Med Microbiol 1997; 8: 15-9
69. Blessing J, Walker J, Maybury B, et al. Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis patients [abstract]. Am Rev Respir Dis 1979; 119: 262
70. Gladman G, Connor PJ, Williams RF, et al. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child 1992; 67: 192-5
71. Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996; 15: 402-5
72. Karpati F, Malmborg AS, Alfredsson H, et al. Bacterial colonisation with Xanthomonas maltophilia: a retrospective study in a cystic fibrosis patient population. Infection 1994; 22: 258-63
73. Ballestero S, Virseda I, Escobar H, et al. Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1995; 14: 728-9
74. Demko CA, Stern RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol 1998; 25: 304-8
75. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27: 158-63
76. Valdezate S, Vindel A, Maiz L, et al. Persistence and variability of S. maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerg Infect Dis 2001; 7: 113-22
77. Talmaciu I, Varlotta L, Mortensen J, et al. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000; 30: 10-5
78. Denton M, Todd NJ, Kerr KG, et al. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol 1998; 36: 1953-8
79. Krzewinski JW, Nguyen CD, Foster JM, et al. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol 2001; 39: 3597-602
80. Hutchinson GR, Parker S, Pryor JA, et al. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gramnegative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996; 34: 584-7
81. Mooney L, Rajgopal A, Denton M, et al. Nebulizer contamination by Stenotrophomonas maltophilia in an adult cystic fibrosis unit [abstract 412]. Pediatr Pulmonol 2000; Suppl. 20: 291
82. De Vidipo LA, De Marques EA, Purchelle E, et al. Stenotrophomonas maltophilia interaction with human epithelial respiratory cells in vitro. Microbiol Immunol 2001; 45: 563-9
83. Huchison ML, Brinell EC, Poston IR, et al. Endotoxic activity of lipopolysaccharides isolated from emergent potential cystic fibrosis pathogens. FEMS Immunol Med Microbiol 2000; 27: 73-7
84. Zughaier SM, Ryley HC, Jackson SK. Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes. Infect Immun 1999; 67: 1505-7
85. Denton M, Hall MJ, Todd NJ, et al. Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium. Clin Microbiol Infect 2000; 6: 397-8
86. King A. Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother 2001; 48 Suppl. S1: 77-80
87. Schmitz F-J, Sadurski R, Verhoef J, et al. Typing of 154 clinical isolates of Stenotrophomonas maltophilia by pulsed-field gel electrophoresis and determination of the in vitro susceptibilities of these strains to 28 antibiotics. J Antimicrob Chemother 2000; 45: 921-4
88. Irifune K, Ishida T, Shimoguchi K, et al. Pneumonia caused by Stenotrophomonas maltophilia with a mucoid phenotype. J Clin Microbiol 1994; 32: 2856-7
89. Schwab U, Gilligan P, Jaynes J, et al. In vitro activities of designed antimicrobial peptides against multi drug-resistant cystic fibrosis pathogens. Antimicrob Agents Chemother 1999; 43: 1435-40
90. Saiman L, Tabibi S, Starner TD, et al. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 2838-44
91. Jevons MP. Celbenin-resistant staphylococci. BMJ 1961; 1: 124-5
92. Jessen O, Rosendal K, Bulow P, et al. Changing staphylococci and staphylococcal infections: a ten-year study of bacteria and cases of bacteremia. N Engl J Med 1969; 281: 627-35
93. Jarvis WR, Martone W. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 Suppl A: 9-24
94. Rossney AS, Pomeroys HM, Keane CT. Staphylococcus aureus phage typing, antimicrobial susceptibility patterns and patient data correlated using a personal computer: advantages for monitoring the epidemiology of MRSA. J Hosp Infect 1994; 26: 219-34
95. Morgan M, Salmon R, Evans-Williams D, et al. Resistance to methicillin in isolates of Staphylococcus aureus from blood and cerebrospinal fluid in Wales, 1993-1997. J Antimicrob Chemother 1999 Oct; 44: 541-4
96. Givney R, Vickery A, Holliday A, et al. Methicillin-resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect 1997; 35: 27-36
97. Rao G, Gaya H, Hodson M. MRSA in cystic fibrosis. J Hosp Infect 1998; 40: 179-91
98. Thomas SR, Gyi KM, Gaya H, et al. Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre. J Hosp Infect 1998; 40: 203-9
99. Boxerbaum B, Jacobs MR, Cechner RL. Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmonol 1988; 4: 159-63
100. Miall LS, McGinley NT, Brownlee KG, et al. Methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001; 84: 160-2
101. Cox RA, Conquest C, Mallaghan C, et al. A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect 1995 Feb; 29: 87-106
102. Romero-Vivas J, Rubio M, Fernandez C, et al. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995 Dec; 21: 1417-22
103. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994 Dec; 150: 1545-9
104. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279: 593-8
105. Solis A, Hughes J, Brown D, et al. Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. 24th European CF conference; Vienna 2001, Vienna
106. Asensio A, Guerrero A, Quereda C, et al. Colonization and infection with methicillin-resistant Staphylococcus aureus: associated factors and eradication. Infect Control Hosp Epidemiol 1996; 17: 20-8
107. Kotilainen P, Routamaa M, Peltonen R, et al. Eradication of methicillin-resistant Staphylococcus aureus from a health center ward and associated nursing home. Arch Intern Med 2001; 161: 859-63
108. Mitsuda T, Arai K, Ibe M, et al. The influence of methicillin-resistant Staphylococcus aureus (MRSA) carriers in a nursery and transmission of MRSA to their households. J Hosp Infect 1999; 42: 45-51
109. Shahin R, Johnson IL, Jamieson F, et al. Methicillin-resistant Staphylococcus aureus carriage in a child care center following a case of disease: Toronto Child Care Center Study Group. Arch Pediatr Adolesc Med 1999; 153: 864-8
110. Rimland D, Roberson B. Gastrointestinal carriage of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 1986; 24: 137-8
111. Sloot N, Siebert J, Hoffler U. Eradication of MRSA from carriers by means of whole-body washing with antiseptic in combination with mupirocin nasal ointment. Zentralbl Hyg Umweltmed 1999; 202: 513-23
112. Hayakawa T, Hayashidera T, Katsura S, et al. Nasal mupirocin treatment of pharynx-colonised methicillin resistant Staphylococcus aureus: preliminary study with 10 carrier infants. Pediatr Int 2000 ; 42: 67-70
113. Bertino Jr JS. Intranasal mupirocin for outbreaks of methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 1997 Oct 1; 54: 2185-91
114. Semeret M, Miller MA. Topical mupirocin for eradication of MRSA colonisation with mupirocin-resistant strains. Infect Control Hosp Epidemiol 2001; 22: 578-80
115. Parras F, Guerrero MC, Bouza E, et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 175-9
116. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance [correction to 1995; 16: 105-13]. Infect Control Hosp Epidemiol 1995; 16: 498
117. Gottlieb T, Mitchell D. The independent evolution of resistance to ciprofloxacin, rifampicin, and fusidic acid in methicillin-resistant Staphylococcus aureus in Australian teaching hospitals (1990-1995). Australian Group for Antimicrobial Resistance (AGAR). J Antimicrob Chemother 1998; 42: 67-73
118. Speller DC, Johnson AP, James D, et al. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-1995. Lancet 1997; 350: 323-5
119. Hashisaki PA, Jacobson JA. Characteristics, control, and treatment of methicillin-resistant Staphylococcus aureus infections. Clin Pharm 1982; 1: 343-8
120. Shimizu K, Orizu M, Kanno H, et al. Clinical studies on vancomycin in the treatment of MRSA infection. Jpn J Antibiot 1996; 49: 782-99
121. British National Formulary. London: British Medical Association 2003; 279, 662
122. Gang RK, Sanyal SC, Mokaddas E, et al. Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns. Burns 1999; 25: 640-4
123. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment at the time of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration in pulmonary function in patients with cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-5
124. Scheel O, Lyon DJ, Rosdahl VT, et al. In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993. J Antimicrob Chemother 1996; 37: 243-51
125. Chang SC, Hsieh SM, Chen ML, et al. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aurcus colonisation and results in emergence of fusidic acid resistant strains. Diagn Microbiol Infect Dis 2000; 36: 131-6
126. Roccaforte JS, Bitmer MJ, Stumpf CA, et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus colonisation with the use of trimethoprim-sulfamethoxazole, rifampicin, and bacitracin. Am J Infect Control 1988; 16: 141-6
127. O'Neil AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 647-50
128. Darouiche R, Wright C, Hamill R, et al. Eradication of colonisation by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampicin and topical mupirocin. Antimicrob Agents Chemother 1991; 35: 1612-5
129. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-82
130. Betrui C, Redondo M, Boloix A, et al. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother 2001; 48: 911-3
131. Bouza E, Muoz P. Linezolid:pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect 2001; 7 Suppl. 4: 75-82
132. Yabuuchi E, Kawamura Y, Kosako Y, et al. Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (Packer and Vishniac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov. and Achromobacter xylosoxidans subsp. denitrificans (Rüger and Tan) comb. nov. Microbiol Immunol 1998; 42: 429-38
133. Dunne Jr WM, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis 1995; 20: 836-41
134. Duggan JM, Goldstein SJ, Chenoweth CE, et al. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis 1996; 23: 569-76
135. Ben Salem N, Salem N, Monastiri K, et al. Neonatal meningitis due to Alcaligenes xylosoxidans contaminating aqueous solution of eosin. Arch Pediatr 1999; 6: 226-7
136. Pan TH, Heidemann DG, Dunn SP, et al. Delayed onset and recurrent Alcaligenes xylosoxidans keratitis. Cornea 2000; 19: 243-5
137. Moissenet D, Baculard A, Valcin M, et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis 1997; 24: 274-5
138. Tan K, Conway SP, Brownlee KG, et al. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002; 34: 101-4
139. Peltroche-Llacsahuanga H, Haase G, Kentrup, H. Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis. Eur J Clin Microbiol Infect Dis 1998; 17: 132-4
140. Vu-Thien H, Moissenet D, Valcin M, et al. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis centre. Eur J Clin Microbiol Infect Dis 1996; 15: 876-9
141. Jensen T, Pedersen SS, Hoiby N, et al. Use of antibiotics in cystic fibrosis. The Danish approach. Antibiot Chemother 1989; 42: 237-46
142. Frederiksen B, Lanng S, Koch C, et al. Improved survival in Danish centre treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996; 21: 153-8
143. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179: 1190-6
144. Lui Z, Cheng Y, San Gabriel P, et al. Alcaligenes species: misidentification and antibiotic resistance. Pediatr Pulmonol 1998; Suppl. 17: 307